Business Wire

Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

2.4.2024 08:00:00 EEST | Business Wire | Press release

Share

Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA and Europe with the ProtEmbo® System, an innovative next generation cerebral embolic protection device (CEP) providing complete 3-vessel coverage of the cerebral arteries. The PROTEMBO study aims to show superiority of the ProtEmbo® System against a hybrid control group: half receiving no CEP and half receiving the Sentinel™ CEP (Boston Scientific, Marlborough, MA, USA), which covers just two of the three cerebral arteries that originate from the aortic arch. The primary diffusion-weighted magnetic resonance imaging (DW-MRI) efficacy endpoint will use a novel adaptive statistical approach that includes pre-specified interim analyses with the possibility of early study completion in the instance of superiority. The primary safety endpoint is the rate of major adverse cardiac and cerebrovascular events (MACCE) assessed at 30-days.

The trial will be led by Dr Susheel Kodali (New York Presbyterian Hospital, NY, USA), Dr Raj Makkar (Cedars Sinai, Los Angeles, CA, USA) and Dr Stephan Haussig (Herzzentrum, Dresden, Germany), as the designated Global Co-Principal Investigators, with Dr Roxana Mehran (Mount Sinai, NY, USA) as the Chair of the Study Executive Committee.

“The novel adaptive statistical design of this clinical study will answer several important unanswered questions about the role of three-vessel cerebral protection in reducing new lesions in all areas of the brain,” said Dr Mehran. “The results will give the physician community increased confidence in offering patients cerebral protection when they undergo their TAVR procedures.”

“We are proud to be the first center to enroll a patient into this innovative international study,” said Dr Kodali. “The requirement for DW-MRI assessment means that we will be able to accurately quantify the fundamental effect of the technology on reducing the size and frequency of new cerebral lesions, which are very common during the TAVR procedure.”

“We are delighted to announce that the first patient has been enrolled in the trial, and that we are executing a cadenced plan to activate the other investigational sites in the next few months. We would like to express our gratitude to the teams at the sites for the hard work that each has invested in the study startup phase. This significant progress reflects the close collaboration between our study executive committee, our clinical research organization, and core lab partners in planning this complex trial,” said Karl von Mangoldt and Conrad Rasmus Co-CEOs of Protembis.

About ProtEmbo® and Protembis

The ProtEmbo® Cerebral Protection System is an intra-aortic filter device that protects the entire brain from embolic material liberated during TAVR. It is a low-profile non thrombogenic system that shields all cerebral vessels, delivered through the left radial artery for optimal placement and stability. This is an ideal access site enabling physicians to avoid interference with TAVR equipment typically delivered through the femoral artery.

Protembis is a privately held emerging medical device company that has developed the ProtEmbo ® Cerebral Protection System. The company strives to provide a simple and reliable solution to protect patients from brain injury during left-sided heart procedures, improving patient quality of life and reducing overall healthcare costs associated with brain injury during such procedures. The ProtEmbo ® System is currently undergoing clinical investigations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Protembis GmbH
Conrad Rasmus & Karl von Mangoldt
+49(0)241 9903 3622
management[at]protembis.com
www.protembis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Summit Risk Partners Limited Opens for Business as a Registered Lloyd’s Broker Through its Regulated Subsidiaries19.11.2026 10:00:00 EET | Press release

Summit Risk Partners Limited (SRP), a newly launched division of K2 Insurance Services, announced today it is officially open for business as a registered Lloyd’s broker. Built specifically for the future of delegated authority, SRP aims to elevate service provision and set a new standard for outcomes across delegated and programme business in the Lloyd’s and London markets. Co-founded by James Baird, CEO, and Jamie Beckett, Managing Director, the specialist broking house operates free from legacy systems and mindsets. SRP combines deep industry expertise with modern technology, actionable insight, and a relentless focus on client success for coverholders, MGAs, underwriting businesses and capacity providers. Key Operational Highlights: Market Status: Registered Lloyd’s broker trading under the pseudonym SUM (Broker Number 2336), sponsored by three leading Lloyd’s Managing Agents. Footprint: Operates in the UK through Summit RP GmbH (UK Branch), an appointed representative of K2 Group

Man & Science Completes Implantation in ONFIELD First-in-Human Study of Miniaturised ONS System for Chronic Cluster Headache19.11.2026 09:00:00 EET | Press release

Man & Science, a Belgian-based medical device company specialised in miniaturised neurostimulation technologies, today announced that all ten patients have been implanted and activated in its ONFIELD first-in-human pilot study of a miniaturised occipital nerve stimulation (ONS) implant for cluster headache, and that early clinical responses are encouraging. The ONFIELD study is evaluating the safety and feasibility of the Man & Science implant in patients whose cluster headaches remain inadequately controlled despite available treatments. All ten patients planned for this stage of the study have now received the implant and are being followed by the participating clinical team. Early observations show reductions in attack frequency in the patients assessed to date. No serious adverse events related to the implant surgery or the device have been reported so far. A severe and difficult-to-treat neurological disorder Cluster headache is a severe neurological disorder characterised by recu

Ant International Launches Whale Orchestration Protocol Under MAS’ BLOOM Initiative to Connect Tokenised Money Market Funds and Tokenised Deposits19.11.2026 08:00:00 EET | Press release

Ant International today announced the launch of the Whale Orchestration Protocol, a major upgrade to its blockchain-based wholesale settlement platform, WhaleRTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118947513/en/ Developed under the Monetary Authority of Singapore’s (MAS) BLOOM1 (Borderless, Liquid, Open, Online, Multi-currency) initiative, the protocol enables seamless Delivery-versus-Payment (DvP) transactions between tokenised deposits and tokenised money market funds. Through WhaleRTP, the Whale Orchestration Protocol enables secure and atomic settlement between tokenised deposits and tokenised money market funds, overcoming traditional fund settlement delays. This unlocks immediate liquidity for the company's real-time global treasury management, allowing idle capital to be deployed in real time. Ant International has already completed pilot transactions in partnership with DBS and Franklin Templeton, who

RSA Compliance Advisor Closes the Governance Gaps Between Audits19.11.2026 08:00:00 EET | Press release

RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced the general availability of RSA Compliance Advisor, a new capability within RSA® Governance & Lifecycle, the RSA identity governance and administration (IGA) solution, that maps identity governance controls directly to regulatory requirements and reports on compliance posture continuously. Governments and regulators keep raising the bar. GDPR, CJIS, HIPAA, NIST, and POPIA each carry hundreds of requirements, and new regulatory activity keeps adding more. Despite growing regulatory requirements, most compliance programs still confirm their posture the way they did a decade ago: quarterly reviews, annual certifications, manually built spreadsheets. This reactive, periodic assessment doesn’t account for access that changes every day in between. A program built on point-in-time checkpoints can look compliant on the day of the audit and still carry risk that never gets seen. RSA Co

NETS and Ant International Deepen Partnership to Empower Singapore’s Businesses for a Future in Agentic Commerce with Agentic Mobile Protocol19.11.2026 07:30:00 EET | Press release

Network for Electronic Transfers (NETS), Singapore’s leading payment services group, and Ant International are deepening their partnership to help businesses across Singapore reach new customers, simplify their operations and thrive in the era of agentic commerce by building a more connected mobile ecosystem well adapted to the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118997808/en/ Lawrence Chan, Group CEO, NETS (L) and Peng Yang, CEO, Ant International (R) NETS and Ant International signed a Memorandum of Understanding (MOU) at the Singapore Fintech Festival 2026 to explore a collaboration that draws on NETS’ digital payments services and Ant International’s Agentic Mobile Protocol (AMP) as well as its full stack of AI-native solutions. The expanded partnership spans several areas of strategic cooperation: Bringing agentic commerce capabilities to businesses of all sizes across Singapore NETS will become th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye